All News
Filter News
Found 133,304 articles
-
Asher Bio Closes $55 Million Series C Financing to Advance Lead Program into Phase 1b Clinical Trials
4/16/2024
Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, today announced the closing of a Series C financing, which raised $55 million.
-
VBI Vaccines Reports Full Year 2023 Financial Results
4/16/2024
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the year ended December 31, 2023.
-
Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings
4/16/2024
Monopar Therapeutics Inc. (Nasdaq: MNPR) today announced that it has filed a provisional patent application pertaining to the recent advancements and optimizations Monopar has achieved with its MNPR-101 radiopharmaceutical program.
-
Evergreen Theragnostics Completes $26M Capital Raise to Advance Novel Radiopharmaceutical Pipeline into the Clinic, Prepare for First Commercial Product Launch, and Expand Industry-Leading CDMO Services
4/16/2024
Evergreen Theragnostics, Inc. today announced the successful completion of a $26M capital raise supported both by existing shareholders and new institutional investors, Petrichor and LIFTT.
-
Chimeron Bio receives NIH (NCI) Innovative Concept Award for mRNA cancer vaccine development
4/16/2024
Chimeron Bio, a Philadelphia -headquartered biotech company, has received a 2024 National Institutes of Health's Small Business Innovation Research Innovative Concept Award through the National Cancer Institute.
-
PacBio Announces Preliminary First Quarter 2024 Revenue and Updates 2024 Revenue Guidance
4/16/2024
PacBio today announced preliminary, unaudited revenue for the quarter ended March 31, 2024.
-
Panbela Announces Transfer to OTCQB Market
4/16/2024
Panbela Therapeutics, Inc., a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, announced that its common stock has been approved for quotation on the OTCQB market.
-
GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent
4/16/2024
GRI Bio, Inc. announced that the Korean Intellectual Property Office has issued a Notice of Patent Grant for Patent Application No. 10-2017-7018579 titled, "Prevention and Treatment of Inflammatory Conditions.".
-
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
4/16/2024
Alvotech and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced that the U.S. Food and Drug Administration has approved SELARSDI injection for subcutaneous use, as a biosimilar to Stelara®, for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older.
-
TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering
4/16/2024
TScan Therapeutics, Inc. announced that it has commenced an underwritten public offering of $125 million of shares of its voting common stock and, in lieu of voting common stock, to certain investors that so choose, pre-funded warrants to purchase shares of voting common stock.
-
Nacuity Pharmaceuticals Expands Board of Directors with Appointment of Dr. Emmett Cunningham, Jr.
4/16/2024
Nacuity Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing novel treatments for retinitis pigmentosa, cataract, and other diseases caused by oxidative stress, announced the appointment of Emmett T. Cunningham, Jr., M.D., Ph.D., MPH, to its board of directors.
-
Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing
4/16/2024
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it is launching its Alternative Methods Advancement Project (AMAP), an initiative dedicated to developing alternatives to reduce animal testing.
-
St. Michael’s Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
4/16/2024
Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that a research team from St. Michael’s Hospital, a site of Unity Health Toronto, has joined the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).
-
Annoviant™ Awarded $2.99 Million NIH Grant to Advance TxGuard™ Pulmonary-Valved Conduit for Pediatric Heart Disease
4/16/2024
Annoviant™, Inc. proudly announces receipt of a $2.99 million grant from the National Institutes of Health.
-
Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement
4/16/2024
Cullinan Therapeutics, Inc. announced that it has entered into a stock purchase agreement with certain institutional and accredited investors for a private placement of approximately $274.0 million of shares of its common stock at a price of $19.00 per share and, in lieu of common stock to certain investors, $6.0 million of pre-funded warrants to purchase shares of its common stock at a price of $18.999 per pre-funded warrant.
-
The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB
4/16/2024
BioArctic AB hereby announces that the Nomination Committee for BioArctic AB presents the following proposals regarding the resolution on the number of board members and the election of board members and Chairperson of the Board at the Annual General Meeting on May 22, 2024.
-
March of Dimes Awards Two Basil O'Connor Grants to Study Triggers of Labor Onset, Barriers to Postpartum Heart Health
4/16/2024
March of Dimes has awarded two doctors the Basil O'Connor Starter Scholar Research Awards, the organization's signature grants for up-and-coming scientists embarking on lifelong research paths.
-
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders
4/16/2024
Ocular Therapeutix, Inc. announced that it has strengthened its clinical development organization with the appointment of Nadia K. Waheed, MD, MPH, as Chief Medical Officer; Peter K. Kaiser, MD as Chief Development Officer; Andrea Gibson, Ph.D., as Vice President, Medical Collaborations; and Namrata Saroj, OD, as Development Strategy Consultant.
-
Cardiawave appoints Olivier Pierron as its Chief Executive Officer
4/16/2024
Cardiawave SA, a French Medtech company that has developed an innovative Non-Invasive Ultrasound Therapy (NIUT) device for the treatment of severe symptomatic calcific aortic stenosis, is delighted to announce the appointment of Olivier Pierron as its new Chief Executive Officer.
-
Imugene and Kincell Bio Announce Strategic Manufacturing and Process Development Partnership
4/16/2024
Imugene, Ltd. and Kincell Bio, LLC, announce a strategic manufacturing and process development partnership, which includes the sale of Imugene’s North Carolina Current Good Manufacturing Practice manufacturing facility and the transfer of process and analytical development activities to Kincell.